These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 10723514

  • 1. Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
    Anderson RD.
    Antivir Ther; 1998; 3 Suppl 4():63-4. PubMed ID: 10723514
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
    Fisher M.
    AIDS; 1998; 12 Suppl 3():S9-16. PubMed ID: 15168718
    [Abstract] [Full Text] [Related]

  • 6. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Krogstad P, Lee S, Johnson G, Stanley K, McNamara J, Moye J, Jackson JB, Aguayo R, Dieudonne A, Khoury M, Mendez H, Nachman S, Wiznia A, Pediatric AIDS Clinical Trials Group 377 Study Team.
    Clin Infect Dis; 2002 Apr 01; 34(7):991-1001. PubMed ID: 11880966
    [Abstract] [Full Text] [Related]

  • 7. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
    Roca B, Gómez CJ, Arnedo A.
    J Infect; 2000 Jul 01; 41(1):50-4. PubMed ID: 10942640
    [Abstract] [Full Text] [Related]

  • 8. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL.
    Antivir Ther; 1999 Jul 01; 4 Suppl 3():85-7. PubMed ID: 16021877
    [Abstract] [Full Text] [Related]

  • 9. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Jul 01; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 10. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J.
    Antivir Ther; 2002 Jun 01; 7(2):81-90. PubMed ID: 12212928
    [Abstract] [Full Text] [Related]

  • 11. [Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
    Aguirrebengoa K, Mallolas J, Uriz J, Torres Tortosa M.
    Enferm Infecc Microbiol Clin; 1996 Oct 01; 14 Suppl 1():3-9. PubMed ID: 9053024
    [No Abstract] [Full Text] [Related]

  • 12. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug 01; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Raffi F, Reliquet V, Ferré V, Arvieux C, Hascoet C, Bellein V, Besnier JM, Breux JP, Garré M, May T, Molina JM, Perré P, Raguin G, Rozenbaum W, Zucman D.
    Antivir Ther; 2000 Dec 01; 5(4):267-72. PubMed ID: 11142621
    [Abstract] [Full Text] [Related]

  • 15. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct 01; 13(73):180-2. PubMed ID: 15499699
    [Abstract] [Full Text] [Related]

  • 16. Stavudine-based multiple agent combinations: initial studies and ongoing comparative trials.
    Murphy RL.
    Antivir Ther; 1998 Oct 01; 3 Suppl 4():69-73. PubMed ID: 10723516
    [Abstract] [Full Text] [Related]

  • 17. New triple combo trial opens.
    Vazquez E, Whitfield L.
    Posit Aware; 1997 Oct 01; 8(6):12. PubMed ID: 11364852
    [Abstract] [Full Text] [Related]

  • 18. [Drug combination therapy for children infected with HIV/AIDS--own experience].
    Prandota-Schoepp A, Klinowska-Skupniewska J.
    Przegl Epidemiol; 2001 Oct 01; 55 Suppl 3():135-41. PubMed ID: 11984940
    [Abstract] [Full Text] [Related]

  • 19. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P.
    J Infect Dis; 2001 Jun 15; 183(12):1732-8. PubMed ID: 11372025
    [Abstract] [Full Text] [Related]

  • 20. Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy.
    Batisse D, Karmochkine M, Si Mohamed A, Piketty C, Kazatchkine MD, Belec L.
    AIDS; 1998 May 07; 12(7):824-5. PubMed ID: 9619820
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.